A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
Cystic fibrosis at end stage — a lifelong genetic disease arriving at its terminal phase in a person who has spent their entire life fighting it. What the hospice team needs to understand on day one.
Cystic fibrosis is an autosomal recessive disease caused by mutations in the CFTR gene (chromosome 7q31.2), which encodes the cystic fibrosis transmembrane conductance regulator — a chloride and bicarbonate channel expressed in epithelial cells throughout the body. CFTR dysfunction produces thick, dehydrated mucus in the airways, pancreatic ducts, biliary system, intestines, and reproductive tract. In the lungs, this mucus creates an environment of chronic infection, inflammation, and progressive bronchiectasis that destroys lung architecture over decades. The adult CF patient who arrives at hospice enrollment has been managing this disease since infancy — daily airway clearance, pancreatic enzyme replacement with every meal, chronic antibiotic therapy, nutritional optimization, and serial pulmonary function monitoring have defined every day of their life.[1]
End-stage CF lung disease is defined by FEV₁ below 30% predicted with progressive decline, increasing exacerbation frequency with incomplete recovery, chronic hypoxemia requiring supplemental oxygen, and often chronic hypercapnia. The airways are colonized with multidrug-resistant organisms — mucoid Pseudomonas aeruginosa in most patients, with Burkholderia cepacia complex, MRSA, Stenotrophomonas maltophilia, or Mycobacterium abscessus in significant subsets. The infection is not eradicable. Hemoptysis — ranging from blood-streaked sputum to massive, life-threatening hemorrhage from bronchial artery erosion — is both a chronic symptom and a potential terminal event. CF-related diabetes (present in ~50% of adults) and pancreatic insufficiency (~85% of patients) add nutritional management complexity unique to CF. The patient is typically 28–52 years old — by far the youngest population in adult hospice.[2]
The hospice clinician entering this home is entering the domain of someone who knows more about their own disease than most clinicians will ever learn. The CF patient has been their own primary disease manager for their entire conscious life. They know their baseline sputum color, their FEV₁ trajectory, their antibiotic sensitivities, and what works for them. They have watched CF friends die. They have made decisions about education, careers, relationships, and children in the shadow of a shortened life expectancy. The transplant that may or may not have been offered — and may or may not have come — is a dimension of grief that permeates every clinical encounter. Clinical humility is not optional in this home. It is the prerequisite for trust.[5]
The CF patient at hospice enrollment is not meeting their disease for the first time. They have been managing it since they could hold a nebulizer. What they need from the hospice team is not education about CF — it is a clinician who will meet them where they already are, who will acknowledge the lifelong nature of this fight, who will not treat them like a textbook case, and who will provide the clinical precision that keeps every remaining day as full and as comfortable as possible. Enter the CF home as a learner. Ask the patient to tell you about their CF. Listen. Build the care plan from what you hear.
CF is diagnosed in childhood in the vast majority of current adult patients. The hospice clinician does not make the diagnosis — but must understand the clinical data that establishes end-stage status and informs every care decision.
The foundational genetic datum. The CFTR mutation genotype determines eligibility for CFTR modulator therapy and has profound prognostic and therapeutic implications at hospice enrollment.
The diagnostic confirmatory test for CF, with prognostic value at hospice enrollment when the patient is on CFTR modulator therapy.
The most important serial data in CF management and the primary hospice eligibility metric.
Chronic airway infection is the defining pathological process in CF lung disease. The sputum culture at hospice enrollment establishes the microbiology that shapes all antibiotic decisions.
High-resolution CT (HRCT) chest documents the structural lung disease that underlies the functional impairment.
CFRD is present in approximately 50% of adults with CF and has significant implications for nutritional management and medication complexity at hospice enrollment.
Nutritional status is a critical prognostic indicator in CF. BMI <18.5 kg/m² in adults is associated with worse outcomes, and nutritional decline accelerates in end-stage disease due to increased caloric demands from the work of breathing.
Your loved one was diagnosed with CF in childhood, and the diagnosis is not in question. What the hospice team reviews in the medical records is the current status of lung function, infection, nutrition, and diabetes — data that tells us exactly where things are today and how best to keep your person comfortable. The tests and numbers in these records are tools the team uses to tailor every part of the care plan to your loved one's specific situation.
Su ser querido fue diagnosticado con fibrosis quística en la infancia, y el diagnóstico no está en cuestión. Lo que el equipo de hospicio revisa es el estado actual de la función pulmonar, la infección, la nutrición y la diabetes — datos que nos permiten mantener a su ser querido lo más cómodo posible.
CFTR protein dysfunction, the polymicrobial infection ecology that drives end-stage lung disease, CF-related comorbidities, and the transplant candidacy factors that shape hospice-relevant clinical decisions.
The CFTR mutation class determines the mechanism of protein dysfunction and the potential for CFTR modulator benefit. Understanding the patient's mutation class contextualizes their modulator history and current eligibility.[6]
The hospice clinician who knows the patient's mutation class can understand why ETI is or is not effective and can communicate this to the family in concrete terms.
The CF airway is a polymicrobial ecosystem where chronic infection drives progressive lung destruction. The organisms present at end stage define the antibiotic options for comfort-directed exacerbation management.[9]
End-stage CF is a multi-system disease. Each comorbidity adds management complexity and affects comfort at hospice enrollment.
Lung transplantation is the only curative option for end-stage CF lung disease. The factors that determine transplant candidacy shape the entire end-stage trajectory and the patient's relationship with hospice enrollment.[18]
Cystic fibrosis is a genetic disease — it was present from the moment of conception. Both parents carry one copy of a mutated CF gene without being affected themselves. Nothing anyone did or didn't do caused CF. Nothing could have prevented it. The progression to end-stage lung disease reflects the relentless nature of this disease despite a lifetime of extraordinary effort by your loved one and their medical teams. The fight that brought your person to this point was real, was brave, and was sustained every single day of their life.
Even at hospice enrollment, genetic counseling referral remains appropriate for family members. Siblings of CF patients have a 2-in-3 chance of being carriers. If the patient has children, they are obligate carriers. The patient's partner should be offered carrier screening. Reproductive implications for surviving family members — particularly siblings of childbearing age — are significant and may be raised by the patient or family during the hospice enrollment period. These conversations can save lives in the next generation.
The full spectrum of CF treatments this patient has received or may still be receiving — from CFTR modulators to airway clearance to lung transplantation. Understanding prior therapy is essential for every hospice care decision.
The adult CF patient at hospice enrollment has typically been on 15–20 medications and treatments, accumulated over decades of progressive disease management. Each treatment was added at a specific point in the disease trajectory for a specific clinical reason. The hospice enrollment requires systematic assessment of every current treatment through a single comfort-benefit question: does this treatment reduce suffering? Some CF standard-of-care treatments are also standard hospice care (PERT — continue; ADEK vitamins — continue; ETI — patient decision). Some require explicit reassessment (inhaled antibiotics, airway clearance vest, tight CFRD glycemic control). And three new comfort medications must be established at the first hospice visit: an opioid for dyspnea, an anxiolytic for the acute panic-dyspnea crisis, and the hemoptysis emergency kit.[4]
The defining pharmacological advance in CF and the most complex medication decision at hospice enrollment.
The lifelong treatment burden that requires end-of-life reassessment. The adult CF patient has typically been performing airway clearance twice daily for their entire life.[20]
The inhaled medication regimen in CF is extensive and time-consuming. Each inhaled medication requires individual comfort-benefit reassessment at hospice enrollment.
CF exacerbation management is antibiotic-driven. The standard model is 14-day IV antibiotic courses, frequently administered at home via PICC line (OPAT).[23]
The only curative option for end-stage CF lung disease — and simultaneously a terrifying gamble with its own terminal trajectory.[18]
Nutritional management in CF is lifelong and does not stop at hospice enrollment. PERT is non-negotiable at every stage.[13]
Specific procedures that may be considered in the hospice setting for symptom management.
Evidence-based criteria for continuing CF-directed therapies within a hospice framework. In CF, many disease-directed treatments are simultaneously comfort-directed treatments. The binary of "treatment vs. hospice" does not apply here.
In cystic fibrosis, the traditional hospice distinction between "disease-directed" and "comfort-directed" therapy breaks down. PERT is disease management and comfort care simultaneously. ETI may reduce mucus viscosity and cough severity — symptom management — while also providing modest disease modification. Inhaled antibiotics suppress bacterial burden that directly causes dyspnea and cough. The hospice clinician must evaluate each CF therapy through its comfort lens, not its disease-modification lens, and many will be continued.[24]
Knowing when treatment has crossed from comfort to burden is the most important clinical skill in end-stage CF. This section names the specific therapies that should be reassessed or discontinued.
The CF patient's treatment regimen has grown over decades — each medication and procedure added at a time when it was appropriate and beneficial. At hospice enrollment, the accumulated treatment burden must be systematically examined. The question is not whether the treatment was ever useful. The question is whether it still reduces suffering today. Some treatments that were essential last year are now producing more burden than benefit. Naming them honestly is a clinical obligation.[24]
The CF patient has spent their entire life being told to do more — more treatments, more airway clearance, more calories, more exercise, more compliance. The hospice enrollment is, for many, the first time a clinician has said: "You've done enough. You can stop what isn't helping. You have earned the right to decide what the rest of your time looks like." This permission — explicit, repeated, and sincere — is therapeutic in itself.
Evidence-graded integrative, interventional, and complementary approaches specific to end-stage CF. Grade A = RCT-supported; B = multi-observational/meta-analysis; C = limited clinical, strong rationale.
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to end-stage CF. The CF supplement landscape is uniquely complex — five safety lenses for every product considered.
Cystic fibrosis creates the most complex supplement safety evaluation in all of respiratory hospice medicine. Every supplement considered for a CF patient must be evaluated through five distinct safety lenses: (1) Pulmonary safety — does this supplement worsen the already severely compromised airway or increase infection risk? (2) CFTR modulator interaction — ETI/Trikafta is metabolized primarily by CYP3A4; any CYP3A4 inhibitor or inducer significantly alters ETI exposure. (3) CF-related diabetes interaction — the CFRD patient managing glucose with insulin is sensitive to any supplement that alters glucose metabolism or insulin sensitivity. (4) Pancreatic insufficiency — absorption of fat-soluble vitamins and fat-containing supplements is impaired in CF patients without adequate PERT; all fat-soluble supplements should be taken with PERT. (5) Infection risk — the immunocompromised CF airway is not further protected by immune-stimulating supplements and some may amplify inflammatory responses in ways that worsen lung function. The CF patient arrives at hospice having been counseled on CF supplement use by their CF team for decades and may have a long-established supplement regimen that should be reviewed rather than dismissed. The fundamental principle is the same as every other hospice diagnosis: does this supplement reduce suffering? If not, it should not be added to an already complex regimen.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| ADEK Vitamins (CF-specific formulation) | Grade A | CF-specific ADEK formulation (e.g., AquADEKs, DEKAs) — per manufacturer dosing; taken with PERT and fat-containing food | CF standard of care. Fat-soluble vitamin deficiency produces: vitamin A deficiency (night blindness, immune dysfunction), vitamin D deficiency (osteoporosis — CF bone disease contributes to rib fractures from coughing, spinal compression fractures), vitamin E deficiency (neurological dysfunction), vitamin K deficiency (coagulopathy, bruising, hemoptysis risk amplification).[33] | Must be taken with PERT for absorption. Vitamin A toxicity possible at high doses — monitor if supplementing beyond CF-specific formulation. Vitamin K supplementation affects INR in patients on warfarin (rare in CF but relevant if present). Vitamin D doses in CF often exceed general population recommendations (1,000–4,000 IU/day or more) — this is appropriate given malabsorption. |
| Omega-3 Fatty Acids (EPA/DHA) | Grade B | EPA 1–2 g + DHA 1–2 g daily; taken with PERT and fat-containing meal | Anti-inflammatory properties. CF patients have documented imbalance in omega-6:omega-3 ratio with excess arachidonic acid metabolites driving airway inflammation. Multiple observational studies suggest improvement in inflammatory markers and possible reduction in exacerbation frequency. Cochrane review found insufficient evidence for strong recommendation but no harm signal.[34] | Must take with PERT for absorption. Mild antiplatelet effect — theoretically relevant in patients with hemoptysis risk, though clinically significant bleeding from fish oil at standard doses is not well documented. GI side effects (fishy taste, burping) may be poorly tolerated. Enteric-coated formulations reduce GI effects. |
| Probiotics | Grade B | Lactobacillus rhamnosus GG or Saccharomyces boulardii — strain-specific dosing per product; 10–20 billion CFU daily | Multiple studies in CF populations show reduced intestinal inflammation, improved GI symptoms (bloating, abdominal pain), and possible reduction in pulmonary exacerbation frequency. The CF gut is dysbiotic from chronic antibiotic exposure, and probiotic supplementation may partially restore microbial balance. Meta-analysis suggests modest benefit for GI comfort.[35] | Generally safe. Theoretical risk of probiotic bacteremia/fungemia in severely immunocompromised patients — clinically rare but documented in case reports. Avoid live yeast (Saccharomyces) in patients with central venous catheters. No significant CYP3A4 interaction with ETI. |
| Ginger (Zingiber officinale) | Grade B | 250–1,000 mg dried ginger extract daily; or fresh ginger tea 2–3 cups daily | Anti-nausea properties — useful for nausea from antibiotic therapy, PERT-related GI discomfort, and opioid-induced nausea. Anti-inflammatory properties may provide modest airway benefit. Well-tolerated in most patients.[36] | Mild antiplatelet effect — same hemoptysis consideration as omega-3. No significant CYP3A4 interaction. May lower blood glucose modestly — monitor in CFRD patients on insulin. GI warmth and reflux possible at high doses. |
| Turmeric / Curcumin | Grade C | 500–1,500 mg curcumin extract daily; bioavailability enhanced with piperine or lipid formulation; take with PERT | Anti-inflammatory and antioxidant properties. Preclinical CF research shows curcumin may improve CFTR trafficking (Class II mutations) — this was an early research finding before modulator development. In end-stage CF, the primary potential benefit is anti-inflammatory symptom management.[37] | CYP3A4 inhibitor — may increase ETI levels. This is the most important drug interaction consideration for turmeric in CF. If the patient is on ETI, turmeric/curcumin supplementation should be discussed with the CF pharmacist. Piperine (black pepper extract) is itself a potent CYP3A4 inhibitor that further amplifies this risk. Antiplatelet effect — hemoptysis consideration. May lower blood glucose — CFRD monitoring. |
| Magnesium | Grade B | 200–400 mg elemental magnesium daily (glycinate or citrate preferred for absorption); take with PERT if using fat-soluble form | Bronchodilator properties — IV magnesium is used for acute bronchospasm; oral supplementation may provide modest airway benefit. Muscle relaxant properties may reduce chest wall muscle fatigue from chronic coughing. Sleep improvement. Constipation relief (particularly relevant given opioid bowel regimen needs).[38] | May cause diarrhea at high doses — counterproductive in CF patients with existing GI issues; titrate slowly. Renal impairment (uncommon in CF unless post-transplant on CNI) increases magnesium accumulation risk. Magnesium citrate useful as part of opioid bowel regimen. No significant CYP3A4 interaction. |
| Melatonin | Grade B | 1–5 mg PO at bedtime; start low (1 mg), titrate for sleep | Sleep disturbance is universal in end-stage CF — from nocturnal cough, dyspnea, oxygen desaturation, anxiety, and the disruption of frequent treatments. Melatonin provides mild sleep onset improvement with minimal next-day sedation. Anti-inflammatory and antioxidant properties may provide modest ancillary benefit. Preferable to benzodiazepine hypnotics for routine sleep support.[39] | Mild CYP1A2 substrate — minimal interaction with ETI (which is CYP3A4). May lower blood glucose slightly — monitor in CFRD patients. Generally very well tolerated. May cause vivid dreams. Headache possible but uncommon. |
| CBD / Cannabis | Grade C | CBD: 10–25 mg PO twice daily, titrate; THC-containing products: per state regulations; avoid smoked/vaped routes | Anxiety reduction, appetite stimulation, nausea reduction, possible anti-inflammatory properties. Appetite stimulation (THC) may be particularly valuable in the cachectic CF patient. Anxiety reduction (CBD) may complement lorazepam for non-acute anxiety management. The CF patient population is often well-informed about cannabis evidence.[40] | CBD is a potent CYP3A4 inhibitor — significantly increases ETI levels. This is a critical interaction. If the patient is on ETI and using CBD, liver function must be monitored (ETI already carries hepatotoxicity risk). THC: psychoactive effects, may worsen anxiety in some patients. Avoid all smoked or vaped cannabis — the CF airway cannot tolerate additional inhaled irritants. Edible or sublingual routes only. May lower blood glucose — CFRD monitoring. Legal status varies by state. |
A guide, not a prediction. The CF trajectory is unique — a lifelong disease since birth reaching its terminal phase in a young adult who has managed it every day of their life. Every patient's path is shaped by CFTR genotype, modulator response, infection ecology, transplant history, and resilience.
The CF timeline is unlike any other diagnosis in hospice. This is not a disease that arrived — it is a disease that has been present since birth, shaping every dimension of the patient's life. The adult CF patient at hospice enrollment has spent decades doing airway clearance, taking enzymes, fighting infections, making career and relationship decisions under the weight of a shortened life expectancy, and watching CF peers die. The timeline below describes not just the terminal phase but the life that preceded it — because the hospice clinician who understands that life provides fundamentally different care than the one who reads only the last chapter.[1] The CFTR modulator era — particularly elexacaftor-tezacaftor-ivacaftor (Trikafta, approved 2019) — has dramatically altered the trajectory for genotype-eligible patients, but patients whose lungs were already destroyed or whose mutations do not respond to current modulators remain on the original natural history curve.[12]
Symptom-targeted pharmacology for adult end-stage CF. The highest baseline medication complexity of any hospice diagnosis — systematic comfort-benefit reassessment of every existing treatment plus three mandatory comfort additions at the first visit.
The adult CF patient arrives with an average of 15–20 medications and treatments established over decades of disease management. Hospice enrollment requires a systematic assessment of every current treatment through the single comfort-benefit question. Some CF standard treatments are also standard hospice care (PERT — always continue; ADEK vitamins — continue; dornase alfa — likely continue; ETI — decision with patient). Some require reassessment (inhaled antibiotics — patient's choice; vest therapy — patient's choice; tight CFRD glycemic control — simplify for comfort). Three new comfort medications must be established at the first visit regardless of prior CF management:
These three additions define the standard of care for CF hospice.[44]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine IR | Opioid / Dyspnea + Cough | 2.5–5 mg PO q4h + PRN | First-line for dyspnea at rest. Liquid oral morphine (MSIR 20 mg/mL) for patients too dyspneic to swallow tablets. SQ morphine 1–2 mg q4h if oral route not possible. Modest antitussive benefit at these doses. If chronic hypercapnia present, start at 2.5 mg and titrate slowly (same approach as COPD). If not hypercapnic, titrate more freely. The opioid that was never prescribed before hospice enrollment must be started at enrollment.[44][45] Monitor for excessive sedation in first 48h; tolerance develops rapidly |
| ETI (Trikafta) | CFTR Modulator / Disease Modification + Symptom Management | 2 tabs AM (elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) + 1 tab PM (ivacaftor 150 mg) | Continuation per patient decision after explicit comfort-benefit conversation. May reduce sputum viscosity, cough burden, and exacerbation frequency even at FEV1 <25%. Take with fat-containing food for absorption. ⚠ CYP3A4 substrate — review all drug interactions. Hospice continuation does not represent inconsistency with comfort goals. Document the comfort-benefit rationale.[12][14] |
| PERT (Pancrelipase) | Pancreatic Enzyme Replacement / GI Absorption | 500–2,500 lipase units/kg/meal; 250–1,250 units/kg/snack | Never discontinue while the patient is eating. Stopping PERT in a pancreatic-insufficient CF patient produces severe abdominal pain, steatorrhea, and GI distress within days. This is one of the most immediately concrete and avoidable comfort failures in CF hospice. Take with every meal and snack. Brand matters to many CF patients — do not substitute without asking.[66] |
| Dornase alfa (Pulmozyme) | Mucolytic / Secretion Management | 2.5 mg nebulized once daily | Continue if providing comfort benefit — reduces sputum viscosity and facilitates clearance. May reduce dyspnea indirectly by improving mucus mobilization. Reassess if the patient can no longer perform airway clearance. Administer 30 min before any airway clearance technique.[54] |
| Hypertonic saline (7%) | Mucokinetic / Secretion Management | 4 mL nebulized BID | Continue if the patient finds it helpful for mucus mobilization. Pre-treat with albuterol to prevent bronchospasm. May be discontinued if treatment burden exceeds comfort benefit at end stage. Patient should guide this decision.[55] |
| Inhaled tobramycin (TOBI) | Inhaled Antibiotic / Pseudomonas Suppression | 300 mg nebulized BID (28 days on/28 days off) | Continue if patient chooses — suppress Pseudomonas burden, may reduce exacerbation frequency. Comfort-benefit reassessment: does the 15–20 min nebulizer time twice daily provide meaningful symptom reduction? The patient who has been on alternating inhaled antibiotics for a decade knows the answer. Ask them.[31] |
| Azithromycin | Macrolide / Anti-inflammatory | 500 mg PO MWF or 250 mg daily | Anti-inflammatory effect in CF airways — reduces exacerbation frequency by approximately 50%. Low burden to continue. Modest GI side effects. Chronic use standard of CF care for most adult patients. Continue unless the patient develops significant GI intolerance.[33][34] |
| Insulin | Hormone / CFRD Management | Individualized — simplify to basal ± rapid correction | CF-related diabetes present in approximately 50% of CF adults. At hospice enrollment, simplify regimen: target glucose 100–250 mg/dL (comfort range). Avoid hypoglycemia above all. Reduce monitoring to once or twice daily. Discontinue sliding scale complexity. The goal is preventing symptomatic hyperglycemia (polyuria, dehydration) and hypoglycemia, not HbA1c optimization.[67][68] |
| ADEK Vitamins | Fat-Soluble Vitamins / Nutritional Support | Per CF-specific formulation (e.g., AquADEKs, DEKAs Plus) | Continue — CF standard of care for pancreatic-insufficient patients. Prevents vitamin D-related bone fragility (rib fractures from coughing), vitamin K coagulopathy (relevant to hemoptysis risk), and vitamin A immune function. Take with PERT for absorption. Low pill burden.[66] |
| Lorazepam | Benzodiazepine / Anxiety-Dyspnea Crisis | 0.5–1 mg SL/PO q4–6h PRN | For acute anxiety-dyspnea episodes. The CF patient at end stage carries specific anxiety — fear of hemoptysis, fear of suffocation, accumulated disease-management anxiety. Sublingual route provides faster onset for acute episodes. Adjunctive to opioid, not replacement. Schedule if breakthrough episodes frequent.[46] |
| Midazolam | Benzodiazepine / Emergency Hemoptysis + Terminal Agitation | 5 mg SQ/IM PRN | Must be drawn, labeled, and positioned in the home at the first visit. Primary indication: massive hemoptysis emergency — administer immediately. Secondary: refractory dyspnea crisis, terminal agitation. Family must be trained on administration. Do not wait for a crisis to position this medication.[48][50] |
| Ondansetron | Antiemetic / Nausea | 4–8 mg PO/ODT/SQ q8h PRN | For nausea from mucus swallowing, opioid initiation, or GI dysmotility. ODT formulation preferred for patients with frequent vomiting. May cause constipation — pair with bowel regimen.[44] |
| Senna/Docusate | Laxative / Opioid-Induced Constipation + DIOS Prevention | Senna 8.6–17.2 mg + docusate 100 mg BID | Mandatory with opioid initiation. CF patients have baseline risk of distal intestinal obstruction syndrome (DIOS) — opioids significantly increase this risk. Aggressive bowel prophylaxis from day one. Titrate senna to effect. Add polyethylene glycol if needed.[66] ⚠ DIOS risk — do not undertreat constipation in CF |
| Albuterol | Beta-2 Agonist / Bronchospasm + Dyspnea | 2.5 mg nebulized q4–6h PRN; or 2 puffs MDI q4h PRN | Continue for bronchospasm and dyspnea relief. Pre-treatment before hypertonic saline. Provides subjective relief of air hunger even when FEV1 response is minimal. Nebulized route preferred for severely dyspneic patients.[56] |
| Ipratropium | Anticholinergic / Bronchospasm + Secretion Management | 0.5 mg nebulized q6–8h PRN | Adjunctive bronchodilator. May reduce secretion volume. Can be combined with albuterol (DuoNeb). Useful in patients with significant mucus hypersecretion contributing to dyspnea.[56] |
High-yield clinical pearls for the hospice team caring for an adult with end-stage CF. The things not in the textbook — learned at the bedside, shaped by a patient population that knows more about their own disease than most clinicians ever will.
The psychosocial landscape of end-stage CF is unlike any other hospice diagnosis — a lifelong disease identity, community grief as collective experience, the transplant that did not come, young dying, and parents who have been caregiving since their child's first breath.
The CF patient arriving at hospice enrollment is typically 28–52 years old. They have lived their entire conscious life with CF. CF is not something that happened to them — it is woven into who they are. Their social identity, their friendships, their career choices, their relationship decisions, their reproductive choices, their daily schedule, their relationship with their body — all have been shaped by CF. The psychological and spiritual distress of end-stage CF is not primarily about dying. It is about losing the structure and purpose that managing the disease has provided for a lifetime — and about the specific, layered, and community-embedded grief that no other disease population carries in quite the same way.[76][77]
Anxiety and depression prevalence in CF adults is approximately 2–3 times the general population rate — the TIDES study documented rates of 32% for elevated depressive symptoms and 22% for elevated anxiety among CF adults. At end-stage, these rates are higher. Screening and treatment are not optional.[75]
The 34-year-old with CF has had CF for their entire conscious life. Their social identity, friendships (often other CF patients), career choices, relationships, reproductive decisions, daily schedule, and relationship with their body have all been shaped by CF. Arriving at end-stage CF does not mean losing a disease — it means losing the framework that organized a life.
The CF patient dying at 34 is dying at an age when their peers are building careers, starting families, and assuming they have decades ahead. The existential distress of young dying in CF is compounded by the knowledge that the CFTR modulator revolution has extended survival for many CF patients — but arrived too late for them.
CF patients form one of the most interconnected disease communities in medicine. They met each other at CF camp as children, at CF clinics as adolescents, and in online communities as adults. Due to infection cross-contamination risk, CF patients are told to stay physically apart — which has made their emotional and digital connections even more intense. When a CF friend dies, the grief is experienced as sibling loss.[76]
Lung transplant is the only curative option for end-stage CF lung disease. Many CF patients at hospice enrollment spent years being evaluated, listed, waiting, and hoping. For some, the transplant was declined by the center (Burkholderia cepacia complex, M. abscessus, psychosocial factors). For some, the call never came. For some, the patient made the agonizing decision to forgo transplant. Each path carries its own grief.[59]
CF affects reproductive function profoundly: approximately 98% of CF males have congenital bilateral absence of the vas deferens (CBAVD) causing obstructive azoospermia; CF females have reduced fertility from thickened cervical mucus. Reproductive decisions made in the shadow of a shortened life expectancy — choosing not to have children, choosing assisted reproduction, choosing adoption, choosing to have a child knowing the genetic risk — may now be sources of grief or complicated legacy. Ask about this gently: "Did CF affect your decisions about having children? Is that something that weighs on you now?"[79]
"The parents of an adult CF patient are not like other hospice caregivers. They have been doing this since their child was diagnosed in infancy. They have administered chest physiotherapy, mixed nebulizers, counted enzyme capsules, fought with insurance companies, driven to CF clinic appointments, sat in hospital rooms during exacerbations, and managed their own terror about their child's prognosis — for 25, 30, 35 years. They are exhausted. They are experts. They may be reluctant to relinquish control to a hospice team they just met. And they are losing their child. Meet them where they are. Acknowledge what they have done. Ask what they need. Do not assume they need to be taught — most of them need to be heard."
Plain language for families. Share, print, or read aloud at the bedside. Written for the parents, partners, siblings, and friends walking alongside someone they love through the final chapter of a lifelong fight with CF.
You know CF. Many of you have known it since your child was diagnosed in infancy, or since your partner first told you about their disease, or since you first understood what your sibling's daily treatments meant. You have lived with this disease alongside the person you love for years or decades. What is happening now is the hardest part — but you are not starting from zero. Everything you have learned, every night you sat in a hospital room during an exacerbation, every enzyme capsule you counted, every treatment session you helped with — all of that prepared you for the care you are giving now. This guide is here to help you understand what to expect, what to do, and when to call for help. You are not alone in this.
Próximamente en español. — Coming soon in Spanish.
People with advanced CF can sometimes cough up significant amounts of blood from damaged blood vessels in their lungs. If this happens:
This event is frightening, but it can be managed with the plan you have. The medications your nurse has positioned reduce suffering immediately. You are prepared for this. Your nurse has made sure of it.
Your person takes pancreatic enzyme capsules with every meal and snack. These enzymes replace what their pancreas cannot make due to CF. Without them, food is not properly digested, causing severe stomach pain, bloating, and diarrhea. Continue giving enzymes with any food, no matter how small the meal. If your person stops eating entirely, the enzymes stop too. Until then, they are essential for comfort.
Coughing up more than a tablespoon of bright red blood — use the hemoptysis plan AND call immediately. Sudden severe difficulty breathing that does not improve with morphine and positioning. New confusion, extreme drowsiness, or difficulty waking — this may indicate CO2 buildup or low blood sugar. Fever above 101°F with worsening cough — may be the beginning of a pulmonary exacerbation that needs treatment. Severe abdominal pain or bloating — could be distal intestinal obstruction (DIOS), which needs prompt attention. Blood sugar below 70 or above 400 in a CFRD patient. Any change that frightens you — you do not need to decide if it's "serious enough." Call. That is what we are here for.
To the CF friends, fellow warriors, and community members who are walking alongside this person: we know that you carry a grief that is both personal and collective. You have lost friends to this disease. You may be fighting your own CF while supporting someone you love. Your presence — whether in person, online, or in spirit — matters profoundly. If there are ways the CF community wants to be involved in care, in visits, or in remembrance, tell us. We will honor what you need.
🙏 You have been doing this longer than most people can imagine. The care you have given — the airway clearance sessions, the hospital stays, the enzyme capsules, the appointments, the advocacy, the love — all of it brought your person to this moment with the best quality of life possible. Research consistently shows that patients with engaged, present caregivers have less pain, less anxiety, and more peace. You are not just watching — you are part of the treatment team, and you have been since the beginning. What you are doing matters. What you have already done is extraordinary.
Clinical field wisdom from 12+ years at the bedside. The things you learn after caring for the youngest patients in adult hospice. Not guidelines — real.
Peer-reviewed citations organized by clinical category. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by study design.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.